AONYS® allows the administration of low doses of water-soluble pharmaceutical active ingredients. The final product is deposited on the mucosa of the mouth and delivered directly into the cells of the whole body
NP03 is a disease-modifying nano dose formulation of lithium citrate in an AONYS® reverse microemulsion. NP03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at low doses.
Preclinical studies on the disease-modifying effect of NP03 in AD have been conducted in McGill University, Montreal CA. NP03 is a disease modifying drug and induced neurogenesis. A phase II is planned for the treatment of psychosis associated with AD.
After a civil or military nuclear accident, there are no suitable decorporation treatments for large contaminated populations and no approved drug to be used after irradiation and free of serious side effects.
The storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication on an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.Technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance by your ISP, or additional third-party records, information stored or retrieved for this purpose alone generally cannot be used to identify you.
Storage or technical access is required to create user profiles to send advertising, or to track the user across one or multiple websites for similar marketing purposes.